We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 62

Second Circuit antitrust decision creates uncer tainty for non-practice of patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 11 2015

The U.S. Court of Appeals for the Second Circuit's recent decision in New York v. Actavis PLC appeared on its face to address a narrow issue of


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


U.S. Supreme Court issues ruling on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Supreme Court has determined that while human genes and the information they encode are not patent eligible, despite the effort required to


Federal court upholds FTC rules on reporting certain pharma patent transfers
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

Granting the agency's motion for summary judgment, a federal court in the District of Columbia has upheld the U.S. Federal Trade Commission's (FTC's


Court finds no standing for Consumer Watchdog in stem cell patent appeal
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The Federal Circuit Court of Appeals has rejected not-for-profit Consumer Watchdog's appeal of the U.S. Patent and Trademark Office's (USPTO's


Ambry Genetics countersues Myriad Genetics in genetic patent infringement suit
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

Responding to the patent infringement claims asserted against it by Myriad Genetics, Ambry Genetics Corp. denies that the 15 patents at issue were


D.C. court relies on Prometheus to find therapeutic selection patents invalid
  • Shook Hardy & Bacon LLP
  • USA
  • April 19 2012

Less than two weeks after the U.S. Supreme Court issued Mayo Collaborative Services v. Prometheus Laboratories, Inc., ruling that methods for determining an optimal drug dosage to treat certain autoimmune diseases were not patent eligible, a federal court in the District of Columbia similarly found that claims for “Systems, Methods and Computer Program Products for Guiding the Selection of Therapeutic Treatment Regimens” are patent-ineligible


Federal Circuit’s patent infringement ruling conflicts with USPTO re-examination on validity
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The Federal Circuit Court of Appeals has denied a request for an en banc rehearing by a medical-device patent holder which argued that the U.S. Patent and Trademark Office’s (USPTO’s) Board of Patent Appeals had effectively nullified a previous Federal Circuit decision on the validity of its patent


Medical treatment claims deemed patentable on reconsideration after Bilski
  • Shook Hardy & Bacon LLP
  • USA
  • January 13 2011

The Federal Circuit Court of Appeals has confirmed its earlier decision, rendered before Bilski v. Kappos, 130 S. Ct. 3218 (2010), was decided, and ruled that methods for determining the optimal dosage of thiopurine drugs used to treat gastrointestinal and non-gastrointestinal autoimmune diseases recite patentable subject matter under 101